Following receipt of additional analyses from the company, the CDF rapid reconsideration topic Trastuzumab emtansine for the treatment of locally advanced or metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane (review of TA371) will be discussed in committee on Tuesday 09 May 2017